Companion Guidance For Combo Products Rule Clears Up Some Gray Areas
This article was originally published in The Silver Sheet
Executive Summary
The draft guidance provides real-world application, examples and detailed instructions for compliance with agency good manufacturing practice rules for drug delivery devices and other drug/device, drug/biological and drug/device/biological products.
You may also be interested in...
Industry Seeks More Clarity Following Combo Product GMP Final Rule
FDA’s final regulation outlines which manufacturing system requirements apply to products that have drug, device and/or biologic components. An industry coalition says key details need to be filled in by FDA with guidance.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.